Payal D. Shah

University of Pennsylvania
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (35)

Purpose: Addition of ataxia telangiectasia and Rad3-related kinase inhibitors (ATRi) to PARP inhibitors (PARPi) overcomes PARPi resistance in high-grade serous ovarian cancer (HGSOC) cell and mouse models. We present the results of an investigator-initiated study of combination PARPi (olaparib) and ATRi (ceralasertib) in patients with acquired PARPi-resistant HGSOC. Patients and Methods: Eligible patients had recurrent, platinum-sensitive BRCA1/2 mutated or homologous recombination (HR)–deficient (HRD) HGSOC and clinically benefited from PARPi (response by imaging/CA-125 or duration of maintenance therapy; > 12 months first-line or > 6 months ≥ second-line) before progression. No intervening chemotherapy was permitted. Patients received olaparib 300 mg twice daily and ceralasertib 160 mg daily on days 1 to 7 of a 28-day cycle. Primary objectives were safety and objective response rate (ORR). Results: Thirteen patients enrolled were evaluable for safety and 12 for efficacy; 62% ( n = 8) had germline BRCA1/2 mutations, 23% ( n = 3) somatic BRCA1/2 mutations, and 15% ( n = 2) tumors with positive HRD assay. Prior PARPi indication was treatment for recurrence (54%, n = 7), second-line maintenance (38%, n = 5) and first-line treatment with carboplatin/paclitaxel (8%, n = 1). There were 6 partial responses yielding an ORR of 50% (95% confidence interval, 0.15–0.72). Median treatment duration was 8 cycles (range 4–23+). Grade (G) 3/4 toxicities were 38% ( n = 5); 15% ( n = 2) G3 anemia, 23% ( n = 3) G3 thrombocytopenia, 8% ( n = 1) G4 neutropenia. Four patients required dose reductions. No patient discontinued treatment due to toxicity. Conclusions: Combination olaparib and ceralasertib is tolerable and shows activity in HR-deficient platinum-sensitive recurrent HGSOC that benefited and then progressed with PARPi as the penultimate regimen. These data suggest that ceralasertib resensitizes PARPi-resistant HGSOCs to olaparib, warranting further investigation.

Year:

2025

Purpose: Addition of ataxia telangiectasia and Rad3-related kinase inhibitors (ATRi) to poly-ADP ribose polymerase inhibitors (PARPi) overcomes PARPi-resistance in high grade serous ovarian cancer (HGSOC) cell and mouse models. We present the results of an investigator-initiated study of combination PARPi(olaparib) and ATRi(ceralasertib) in patients with acquired PARPi-resistant HGSOC. Patients and Methods: Eligible patients had recurrent, platinum-sensitive BRCA1/2 mutated or homologous recombination (HR) deficient HGSOC and clinically benefited from PARPi (response by imaging/CA-125 or duration of maintenance therapy; >12 months 1 st -line or >6 months ≥2 nd -line) before progression. No intervening chemotherapy was permitted. Patients received olaparib 300mg twice daily and ceralasertib 160mg daily on days 1-7 of a 28-day cycle. Primary objectives were safety and objective response rate (ORR). Results: Thirteen patients enrolled were evaluable for safety and 12 for efficacy. 62%(n=8) had germline BRCA1/2 mutations, 23% (n=3) somatic BRCA1/2 mutations, and 15%(n=2) HR-deficient tumors. Prior PARPi indication was treatment for recurrence (54%, n=7), 2nd line-maintenance (38%, n=5), and frontline treatment with carboplatin/paclitaxel (8%, n=1). There were 6 partial responses yielding an ORR of 50% (95% CI:0.15, 0.72). Median treatment duration was 8 cycles (range 4-23+). Grade(G) 3/4 toxicities were 38%(n=5); 15%(n=2) G3 anemia, 23%(n=3) G3 thrombocytopenia, 8% (n=1) G4 neutropenia. Four patients required dose-reductions. No patient discontinued treatment due to toxicity. Conclusion: Combination olaparib and ceralasertib is tolerable and shows activity in HR-deficient platinum-sensitive recurrent HGSOC that benefited and then progressed with PARPi as the penultimate regimen. These data suggest that ceralasertib re-sensitizes PARPi resistant HGSOCs to olaparib, warranting further investigation.

Year:

2024

Germline pathogenic variants (PVs) in the BRCA1 and BRCA2 genes confer elevated risks of breast, ovarian, and other cancers. Lynch syndrome (LS) is associated with increased risks of multiple cancer types including colorectal and uterine cancers. Current cancer risk mitigation strategies have focused on pharmacologic risk reduction, enhanced surveillance, and preventive surgeries. While these approaches can be effective, they stand to be improved on because of either limited efficacy or undesirable impact on quality of life. The current review summarizes ongoing investigational efforts in cancer risk prevention strategies for patients with germline PVs in BRCA1, BRCA2, or LS-associated genes. These efforts span radiation, surgery, and pharmacology including vaccine strategies. Understanding the molecular events involved in the premalignant to malignant transformation in high-risk individuals may ultimately contribute significantly to novel prevention strategies.

Year:

2024

Supplemental Figure 7. B7-H4 and PD-L1 are not mutually exclusive on tumor cells. Data shown are reverse phase protein array expression data of B7-H4 and PD-L1 (SP142, 22C3, or Atezolizumab) from the I-SPY2 patient cohort. Samples were a mixture of TNBC and ER+ tumors and were treated with chemotherapy ± anti-PD-1. Depending on the antibody clone selected to detect PD-L1 expression, B7-H4 had no correlation, or a positive correlation to PD-L1 expression in these tumors. Data analyzed by spearman correlation and shown with linear regression best-fit line. n = 151 patients.

Year:

2024

Supplemental Figure 5. CD45+ gene expression changes from early and later tumor stage between EMT6 control and B7-H4+ tumors. (A) CD45+ cells were isolated from EMT6 control or B7-H4+ tumors 7 days post treatment with isotype control antibody. Differentially expressed genes are shown. n = 6 mice per group. (B) Macrophage function was upregulated in B7-H4+ tumors, but minimal other differences were seen. (C) Differentially expressed genes between control and B7-H4+ tumors at a later stage. n = 12 mice per group. CD45+ cells were harvested when tumors reached 500mm3. (D) Macrophage function remains elevated in B7-H4+ tumors, but minimal differences were detected. Data were analyzed by Wilcoxon rank sum test. Genes with log2 fold change >0.5 or

Year:

2024

Supplemental Figure 5. CD45+ gene expression changes from early and later tumor stage between EMT6 control and B7-H4+ tumors. (A) CD45+ cells were isolated from EMT6 control or B7-H4+ tumors 7 days post treatment with isotype control antibody. Differentially expressed genes are shown. n = 6 mice per group. (B) Macrophage function was upregulated in B7-H4+ tumors, but minimal other differences were seen. (C) Differentially expressed genes between control and B7-H4+ tumors at a later stage. n = 12 mice per group. CD45+ cells were harvested when tumors reached 500mm3. (D) Macrophage function remains elevated in B7-H4+ tumors, but minimal differences were detected. Data were analyzed by Wilcoxon rank sum test. Genes with log2 fold change >0.5 or

Year:

2024

Supplemental Figure 4. B7-H4 expression did not change quantity of infiltrating tumor immune cells in vivo regardless of anti-PD-L1 treatment. Untreated and anti-PD-L1 treated EMT6 tumors ± B7-H4 were dissociated to single cell suspension and subjected to flow cytometry with a 14 (for myeloid cells) or 17 (for T cells) color panel on a CyTEK Aurora. n = 3/group for control and 8/group for treated samples. Data were analyzed by One-way ANOVA with Sidak’s post-hoc test for multiple comparisons between the EMT6 control anti-PD-L1 and EMT6 B7-H4+ anti-PD-L1 treatment groups. One-way ANOVA was not significant between groups. Data were analyzed in GraphPad Prism v10.

Year:

2024

Supplemental Figure 3. B7-H4 was expressed on some tissue immune cells in the C57BL/6 model, but not the BALB/c model. (A) Formalin-fixed, paraffin-embedded sections of BALB/c and C57BL/6 mice were stained for B7-H4, CD45, and DAPI using multiplexed immunofluorescence, or B7-H4 by IHC. CD45+ B7-H4+ cells were observed in spleen and intestine in C57BL/6 mice but not BALB/c mice. (B) Based on morphological characterization, these are likely macrophages. BALB/c spleen, intestine, and other healthy tissues examined (lymph node, fat pad, lung) had no B7-H4+ immune cells. Scale bar 20µm. (C) Flow cytometry of B7-H4+ cells are not present in the BALB/c spleen but are in the C57BL/6 spleen, similar to our findings by mIF. (D) Representation of flow cytometry scatter plots. B7-H4+ immune cells were only found in the C57BL/6 spleen, not bone marrow (b.m.)

Year:

2024

B7-H4 expression is regulated by PI3K signaling. A, Spearman correlations in protein expression from RPPA data collected from patients from the ISPY2 trial. Key positive correlations are called out in blue and key negative correlations are called out in red. B, RPPA data show strong positive correlations between B7-H4 and AKT (pAKT-Ser 473) and strong negative correlations between B7-H4 and PTEN (Ser 380) regardless of tumor hormone receptor status. C, PI3K inhibitor (buparlisib) treatment for 72 hours robustly decreases B7-H4 expression in human MDA-MB-468 breast cancer cells, while MEK inhibitor (trametinib) has no effect. D, Likewise, in MMTV-neu cells, buparlisib reduces B7-H4 expression in dose-dependent manner after 72 hours. Data were analyzed by one-way ANOVA with Dunnet post hoc test for multiple comparisons, P P = 0.0005).

Year:

2024

B7-H4 is associated with immune cold tumors and correlated with worse outcomes. A, Representative TNBC samples (residual disease, post-NAC) categorized on the basis of CD8 T-cell infiltration and localization into ID, MR, SR, and FI. B, B7-H4 is heterogeneously expressed in TNBC. C, ID and MR tumors have the highest level of B7-H4 expression ( n = 69: ID: 19, MR: 17, SR: 14, FI: 19). MR and SR tumors were analyzed by unpaired t test. D, MR and ID tumors also have worse RFS and OS ( n = 69). Data were analyzed by Mantel–Cox test. E, B7-H4 expression directly correlates with worse outcomes in patients ( n = 77; >60%: 16, F, TNBC samples stained with immunofluorescent markers for DAPI, panCK, CD3, and CD8 to identify regions of interest (ROI) for NanoString GeoMX DSP. MR and SR panCK+ ROIs were selected and differential protein expression between tumor samples is shown. G, Within the panCK gated cells, MR tumors had higher EpCAM expression. SR tumors had higher CD44 expression, as well as higher PD-L1. Data shown are log 2 fold change of differentially expressed genes ( P q

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (24)

Susan Domchek

Professor, Clinician-Educator

University of Pennsylvania

UNITED STATES
View details

Vijaya Bharti

Research assistant professor

Vanderbilt University

UNITED STATES
View details

Lainie Martin

University of Pennsylvania Perelman School of Medicine

UNITED STATES
View details

Justin M. Balko

Vanderbilt University Medical Center

UNITED STATES
View details

Fiona Simpkins

-

UNITED STATES
View details

brian lehmann

Research Assistant Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Janos Tanyi

Assistant Professor

University of Pennsylvania

UNITED STATES
View details

Xiaopeng Sun

Vanderbilt University

UNITED STATES
View details

Tarah Ballinger

Associate Professor of Medicine

Indiana University School of Medicine

UNITED STATES
View details

Gillian Hirst

Associate Professor

University of California, San Francisco

UNITED STATES
View details

Rosa Isela Gallagher

Senior Research Scientist

George Mason University

UNITED STATES
View details

Luc Van Kaer

Vanderbilt University School of Medicine

UNITED STATES
View details

Cesar Santa-Maria

Associate Professor

Johns Hopkins University

UNITED STATES
View details

Drew Torigian

Professor, Clinician-Educator

University of Pennsylvania

UNITED STATES
View details

Ie-Ming Shih

Professor

Johns Hopkins University

UNITED STATES
View details

Juliana Bronzini

Vanderbilt University

UNITED STATES
View details

Laura Esserman

University of California

UNITED STATES
View details

Ronny Drapkin

Franklin Payne Professor of Pathology in Obstetrics and Gynecology

University of Pennsylvania

UNITED STATES
View details

Claudine Isaacs

Professor of Medicine

Georgetown University

UNITED STATES
View details

Laura J. van 't Veer

University of California, San Francisco

UNITED STATES
View details

LAMORNA SWIGART

University of California, San Francisco

UNITED STATES
View details

John T. Wilson

Vanderbilt University

UNITED STATES
View details

Vandana Abramson

Professor of Medicine

-

UNITED STATES
View details

Stephanie Gaillard

Johns Hopkins University

UNITED STATES
View details